Fairvalue-Calculator Fairvalue-Calculator
EN DE

Sewoon Medical Co (100700) Fair Value & Analysis

Healthcare · KR · Market cap 94.1B KRW

Price2,160 KRW
Fair Value6,054 KRW
Upside+180.3%
Quality92/100
Evidence: High Range 4,540 KRW – 7,567 KRW

Fair value as of: Jun 25, 2026

✦ Find undervalued quality stocks — 34,000+ analysed Find stocks →

Analysis

Sewoon Medical Co (100700) currently trades at 2,160 KRW, while our model-based Fair Value estimate is 6,054 KRW — implying the stock looks roughly 180.3% undervalued today. We read business quality at 92/100 (high quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: high) — always confirm before acting.

About the company

Sewoon Medical Co., Ltd. engages in the research and development, manufacture, and sale of medical products. Its products include wound drainage systems, urinary catheters and tubes, drainage catheters and tubes, respiratory and tracheal tubes, infusion catheters and tubes, and wound care products. The company also offers unigel, thermosens, epistim, bonastent, and other products. Sewoon Medical Co., Ltd. was founded in 1982 and is headquartered in Cheonan, South Korea.

Open the full interactive analysis →

Similar stocks

InBody Co (041830) +8% i-SENS, Inc (099190) -84% Value Added Technology Co (043150) +214% Mediana Co (041920) +6% Meta Biomed Co (059210) +176% Medicon Hellas S.A (MEDIC) -35%

Frequently asked questions

Is Sewoon Medical Co (100700) undervalued?
As of Jun 25, 2026, our model estimates a fair value of 6,054 KRW versus a price of 2,160 KRW — about +180% (undervalued). Model-based estimate, not financial advice.
What is the fair value of 100700?
Our 21-model fair value for Sewoon Medical Co is 6,054 KRW (as of Jun 25, 2026), built from audited fundamentals. The current price is 2,160 KRW.
What is the quality score of 100700?
Sewoon Medical Co has a Quality Score of 92/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.